 |
|
|
| |
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202
|
| |
| |
Reported by Jules Levin
19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 -24 May2018, Baltimore, Maryland, USA
Cindy J. Bednasz, PharmD, MS 1*Charles S. Venuto, PharmD,1,2Qing Ma, PhD,1Eric S. Daar, MD,3Paul E. Sax, MD,4Margaret Fischl, MD,5Ann C. Collier, MD,6Kimberly Y. Smith, MD, MPH,7Camlin Tierney, PhD,8Edward P. Acosta, PharmD,9Donald E. Mager, PharmD, PhD,10and Gene D. Morse, PharmD1on behalf of the AIDS Clinical Trials Group Study A5202 Team
1AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA; 2 Center for Human Experimental Therapeutics, University of Rochester, Rochester, NY, USA; 3 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the University of California, Los Angeles, CA, USA; 4 Division of Infectious Diseases and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; 5 University of Miami School of Medicine, Miami, FL, USA; 6 University of Washington School of Medicine and Harborview Medical Center, Seattle, WA, USA; 7 ViiVHealthcare, Research Triangle Park, NC, USA. 8 Statistical Data Analysis Center, Harvard T.H. Chan School of Public Health, Boston, MA, USA; 9Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA. 10 Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
|
| |
|
|
|
|
|
